Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8466920 | 0.79 | — | — | |
| SCHEMBL7987385 | 0.78 | NPC1 (0.31) | — | |
| SCHEMBL28330955 | 0.77 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2ATDP1LMNA | |
| SCHEMBL177278 | 0.77 | GABRA1 (0.38) | GABRA1GABRB2 | |
| SCHEMBL19210369 | 0.75 | KDM4E (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL19210370 | 0.75 | KDM4E (0.33) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14058825 | 0.71 | — | — | |
| SCHEMBL6840967 | 0.71 | — | — | |
| SCHEMBL28322651 | 0.69 | GABRA1 (0.37) | GABRA1GABRB2 | |
| SCHEMBL177368 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2004-04-08 | — | — | US | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067531-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | ABL1, LCK, PNCK | GABRA1 2933/4885GABRB2 1902/4885ALDH1A1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.